Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10138221 Salts of nilotinib and polymorphs thereof

Patent 10138221 was granted and assigned to Sun Pharmaceutical on November, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Sun Pharmaceutical

Current Assignee

Sun Pharmaceutical

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

November 27, 2018

Patent Application Number

15503144

Date Filed

August 10, 2015

Patent Citations Received

US Patent 12064428 Kinase inhibitor salts and compositions thereof

0

US Patent 11007195 Kinase inhibitor salts, and compositions thereof

US Patent 11052088 Kinase inhibitor salts, and compositions thereof

US Patent 12064430 Kinase inhibitor salts and compositions thereof

0

US Patent 10940149 Kinase inhibitor salts and compositions thereof

Patent Primary Examiner

Alexander R Pagano

Patent abstract

The present invention provides novel salts of nilotinib and polymorphs thereof. The acid addition salts of nilotinib with benzenesulfonic acid, butanedisulfonic acid, 1-5-naphthalenedisulfonic acid, naphthalene-1-sulfonic acid and 1-hydroxynaph-thoic acid; hydrates and anhydrates thereof.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10138221 Salts of nilotinib and polymorphs thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.